Search results for "harm"

showing 10 items of 13866 documents

Multidisciplinary system for detecting medication errors in antineoplastic chemotherapy.

2009

Objective. To analyze medication errors (MEs) in a multidisciplinary system with a Computerized Pharmacotherapy Process (CPP) in cancer patients. Design. A longitudinal, prospective 2-year (January 2003 —to December 2004) cohort study was made in adult patients administered antineoplastic treatment in Services of Oncology and Haematology. MEs were identified by double cross-validation of each stage of the pharmacotherapeutic process (prescription, preparation, dispensing, administration, and follow-up) carried out by the multidisciplinary team (physician, pharmacist, nurse) with CPP assistance. Variables. Number of MEs per 1000 patient-days, percentage according to the stage of the pharmac…

medicine.medical_specialtyMedication Systems Hospitalanimal structuresInterprofessional RelationsPharmacistNursesAntineoplastic AgentsPharmacistsCohort StudiesHospitals UniversityPharmacotherapyMultidisciplinary approachAntineoplastic chemotherapyPhysiciansmedicineHumansMedication ErrorsPharmacology (medical)Longitudinal StudiesProspective StudiesMedical prescriptionStage (cooking)Adult patientsbusiness.industrySurgeryOncologyEmergency medicinebusinessCohort studyFollow-Up StudiesJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Documento de consenso sobre asma y tabaquismo del Foro Autonómico de Asma de la SEPAR

2021

La prevalencia de tabaquismo activo en adultos con asma es similar a la de la población general. El tabaquismo se asocia con un peor control clínico de la enfermedad, una disminución acelerada de la función pulmonar y una respuesta irregular a la terapia con glucocorticoides. El consumo de tabaco impacta negativamente en la calidad de vida de los pacientes asmáticos y provoca un incremento en el número de visitas y de hospitalizaciones por exacerbaciones. Además, el tabaquismo aumenta el riesgo de cáncer de pulmón, comorbilidades cardiovasculares y muerte en pacientes asmáticos. A pesar de todo ello, las guías actuales del manejo del asma no incluyen recomendaciones específicas para el mane…

medicine.medical_specialtyMedicine (miscellaneous)DiseaseConsesusRecommendationsPharmacological treatmentInternal medicinemedicineTratamientoLung cancerSuspected asthmaAsmaAsthmabusiness.industrySmokingmedicine.diseaseResponse to treatmentTabaquismoAsthmarespiratory tract diseasesTreatmentPsychiatry and Mental healthConsensoRecomendacionesCombined therapyDifferential diagnosisbusiness
researchProduct

In vivo antihypertensive mechanism of lactoferrin-derived peptides: Reversion of angiotensin I- and angiotensin II-induced hypertension in Wistar rats

2015

Novel peptides with antihypertensive effects in SHR rats have previously been identified in lactoferrin (LF) hydrolysates. To investigate their in vivo antihypertensive mechanism, we have assessed the blood pressure lowering effects of two of these LF-derived peptides (RPYL and DPYKLRP) in Wistar rats subjected to either angiotensin I- or angiotensin II-induced hypertension. Blood pressure was measured by the tail-cuff method, hypertension was induced by subcutaneous infusion of angiotensins, and then captopril, valsartan or LF-derived peptides orally administered. Angiotensin I- and angiotensin II-induced hypertension were reversed by captopril and valsartan, respectively. RPYL and DPYKLRP…

medicine.medical_specialtyMedicine (miscellaneous)Lactoferrin-derived peptidesPharmacologyWistar ratAntihypertensive peptidesInternal medicineRenin–angiotensin systemMedicineTX341-641Angiotensin-induced hypertensionNutrition and DieteticsAngiotensin II receptor type 1biologyNutrition. Foods and food supplybusiness.industryCaptoprilAngiotensin-converting enzymeAngiotensin IIBlood pressureEndocrinologyValsartanbiology.proteinRenin angiotensin systemmedicine.symptombusinessVasoconstrictionFood Sciencemedicine.drugIn vivo ACE inhibition
researchProduct

Comprehensive pharmacokinetic model of insulin Glargine and other insulin formulations.

2005

In this paper, a comprehensive pharmacokinetic model for different insulin formulations including insulin Glargine is developed based on the model proposed by Trajanoski et al. (1993). Current models show limitations for insulin Glargine due to the appearance of an uncharacteristic peak in the concentration-time evolution of plasma insulin that does not coincide with real experimental data. This important limitation has been solved in this paper by introducing a new virtual insulin state called the bound state, in addition to the dimeric and hexameric ones. Trying to describe the retarded action of insulin Glargine, the modeling idea behind this approach is that immediately after the subcut…

medicine.medical_specialtyMetabolic Clearance Ratemedicine.medical_treatmentBiomedical EngineeringInsulin GlargineModels BiologicalInsulin Infusion SystemsPharmacokineticsInternal medicinemedicineApplied mathematicsHumansInsulinComputer SimulationSpatial diffusionMathematicsInsulin glargineInsulinDrug Therapy Computer-AssistedInsulin Long-ActingExogenous insulinEndocrinologyLiverPatient behaviorPlasma insulinmedicine.drugIEEE transactions on bio-medical engineering
researchProduct

Exploring gastric emptying rate in minipigs: Effect of food type and pre-dosing of metoclopramide.

2018

The present study investigated the gastric emptying rate in Gottingen minipigs pre- and post-prandial and evaluated the effect of metoclopramide on the same parameter, using paracetamol as an absorption marker. The pharmacokinetic evaluation of the obtained plasma concentration data for paracetamol demonstrated that the fastest gastric emptying rate was observed in the animals that were allowed access to normal pig food. There was no significant difference in the stomach emptying rate observed between fasted and fed minipigs, when fed either with a FDA standard breakfast or a nutritional energy drink. Pre-dosing minipigs with metoclopramide (0.2 or 0.4 mg/kg) did not demonstrate any effect …

medicine.medical_specialtyMetoclopramideMetoclopramideSwinePharmaceutical ScienceGastric emptying030226 pharmacology & pharmacyGastroenterology03 medical and health sciences0302 clinical medicinePharmacokineticsInternal medicinemedicineAnimalsDrug InteractionsDosingAcetaminophenFood typeGastric emptyingbusiness.industrydigestive oral and skin physiologyFastingAnalgesics Non-NarcoticFasted stateStomach emptyingAcetaminophenDopamine D2 Receptor AntagonistsGastric EmptyingFood030220 oncology & carcinogenesisFed stateAntiemeticsSwine MiniatureFemalebusinessmedicine.drugFederal stateMini-pigsEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-contro…

2009

Background Mastocytosis is characterized by the accumulation and activation of mast cells in different organs, most commonly the skin. Miltefosine, a raft modulator, has recently been shown to inhibit the activation of mast cells and to reduce mast cell-driven skin inflammatory responses. Objectives To study the safety and efficacy of topical miltefosine treatment of skin lesions in patients with mastocytosis. Methods Thirty-nine adult patients with mastocytosis with skin involvement were treated in a double-blind, placebo-controlled, parallel trial with topical miltefosine and clobetasol for 2 weeks. Treatment areas were analysed for changes in skin lesions and symptoms following mechanica…

medicine.medical_specialtyMiltefosinebusiness.industryCutaneous MastocytosisProvocation testPlacebo-controlled studyDermatologyMast cellDermatologylaw.inventionmedicine.anatomical_structurePharmacotherapyRandomized controlled trialDermislawMedicinebusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale A…

2012

Purpose To examine the way in which specific drug treatments for Alzheimer's disease are used and whether their use complies with clinical practice guidelines issued by the French National Authority for Health in patients with Alzheimer's disease. Methods We analysed a cross-section of the French National Alzheimer's databank (BNA). Participants were individuals who consulted centres contributing to the BNA in 2010 and diagnosed with Alzheimer's disease and with at least one Mini Mental State Examination (MMSE) score recorded during the course of the year. Results Of 191 919 consultations recorded in the database, 29.9% involved a diagnosis of Alzheimer's disease, and 26 809 patients had co…

medicine.medical_specialtyMini–Mental State Examinationmedicine.diagnostic_testEpidemiologyCross-sectional studybusiness.industrymedicine.drug_classMemantineDiseasePharmacoepidemiologymedicine.diseaseAcetylcholinesterase inhibitorInternal medicinemedicinePharmacology (medical)Alzheimer's diseaseMedical prescriptionPsychiatrybusinessmedicine.drugPharmacoepidemiology and Drug Safety
researchProduct

PGC-1α: a master gene that is hard to master

2012

Peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) is a transcriptional coactivator that favorably affects mitochondrial function. This concept is supported by an increasing amount of data including studies in PGC-1α gene-deleted mice, suggesting that PGC-1α is a rescue factor capable of boosting cell metabolism and promoting cell survival. However, this view has now been called into question by a recent study showing that adeno-associated virus-mediated PGC-1α overexpression causes overt cell degeneration in dopaminergic neurons. How is this to be understood, and can these seemingly conflicting findings tell us something about the role of PGC-1α in cell stress and in cont…

medicine.medical_specialtyModels NeurologicalSettore BIO/11 - Biologia MolecolareRNA-binding proteinBiologyMitochondrionSettore BIO/09 - FisiologiaMiceCellular and Molecular NeuroscienceHeat shock proteinInternal medicinemedicineAnimalsHomeostasisHumansReceptorMolecular BiologyTranscription factorHeat-Shock ProteinsMice KnockoutPharmacologyPGC-1α Mitochondria Dopaminergic neurons Transgenic animal Adenovirus Parkinson’s diseaseDopaminergic NeuronsDopaminergicRNA-Binding ProteinsParkinson DiseaseCell BiologyPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaMitochondriaEndocrinologyCell metabolismNerve DegenerationTrans-ActivatorsMolecular MedicineNeuroscienceHomeostasisTranscription FactorsCellular and Molecular Life Sciences
researchProduct

Neuronal and extraneuronal uptake and efflux of catecholamines in the isolated rabbit heart

1974

1. Isolated rabbit hearts were perfused with (−)-noradrenaline, (−)-adrenaline and (±)-isoprenaline for various time periods (1–180 min) and then washed with an amine-free medium. The venous concentration of the amine was estimated fluorimetrically during the infusion and after its end, to study removal and efflux, respectively. 2. In untreated hearts and after pretreatment with reserpine the removal had a constant rate over 20–60 min. After pretreatment with pargyline to block monoamine oxidase (MAO), however, the removal of noradrenaline declined exponentially to zero. Inhibition of the neuronal uptake (desipramine) and chemical sympathectomy (6-hydroxydopamine) abolished the removal of n…

medicine.medical_specialtyMonoamine Oxidase InhibitorsReserpineTime FactorsEpinephrineMonoamine oxidaseStimulationModels BiologicalHydroxydopaminesNorepinephrineCatecholaminesHeart RateDesipramineIsoprenalineInternal medicinemedicineAnimalsNeuronsPharmacologyChemistryMyocardiumDesipramineIsoproterenolGeneral MedicineCompartment (chemistry)ReserpinePargylinePerfusionEndocrinologyPargylineRabbitsEffluxHalf-Lifemedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct

The neuronal efflux of noradrenaline: Dependency on sodium and facilitation by ouabain

1974

Rabbit hearts were isolated after pretreatment with the MAO inhibitor pargyline and with reserpine and were perfused with 200 ng/ml noradrenaline for 1 h. During the subsequent wash-out with an amine-free solution for 2 h, the neuronal efflux of noradrenaline declined mono-exponentially with a mean halftime of 42 min. Both Na+-free solution and ouabain caused facilitation of the efflux which thereafter declined in a multi-exponential fashion. The maximum facilitation was reached after 3 min of Na+-free perfusion and 25 min after introduction of ouabain. The amount of exogenous noradrenaline accumulated in the heart was only partially released when the extracellular Na+-concentration was nor…

medicine.medical_specialtyMonoamine Oxidase InhibitorsReserpineTime FactorsSodiumchemistry.chemical_elementAdrenergicOuabainNorepinephrineHeart RateInternal medicinemedicineExtracellularAnimalsOuabainNeuronsPharmacologyMyocardiumSodiumGeneral MedicineReserpinePargylineEndocrinologyPargylinechemistryRabbitsEffluxPerfusionmedicine.drugNaunyn-Schmiedeberg's Archives of Pharmacology
researchProduct